Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ASTEROID:A Phase I Trial of ASTX660 in Combination With Pembrolizumab in Patients With Solid Tumours: Utilizing Triple IAP Blockade as a Strategy to Maximize Immunogenic Cell Death and the Generation of an Efficient Adaptive Immune Response

NCT05082259 is registered in ClinicalTrials.gov with Institute of Cancer Research, United Kingdom as lead sponsor.

NCT NCT05082259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05082259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ASTEROID:A Phase I Trial of ASTX660 in Combination With Pembrolizumab in Patients With Solid Tumours: Utilizing Triple IAP Blockade as a Strategy to Maximize Immunogenic Cell Death and the Generation of an Efficient Adaptive Immune Response
Lead sponsor
Institute of Cancer Research, United Kingdom
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 2, 2022
Completion date
December 31, 2026
Enrollment
61 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, cervical cancer, triple negative breast cancer